IMUNON Enters Into CRADA For Preclinical Studies Of PlaCCine Modality In Preventive Vaccines Against Lassa Virus
Portfolio Pulse from Benzinga Newsdesk
IMUNON has entered into a Cooperative Research and Development Agreement (CRADA) for preclinical studies of its PlaCCine modality in preventive vaccines against the Lassa virus. The CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidates in animal models.
August 24, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IMUNON's entry into a CRADA for preclinical studies of its PlaCCine modality in preventive vaccines against the Lassa virus could potentially boost its stock in the short term.
The news of IMUNON entering into a CRADA for preclinical studies of its PlaCCine modality in preventive vaccines against the Lassa virus is directly related to the company's core business. This could potentially lead to a new product offering, which could boost the company's revenues and, consequently, its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100